Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KER-047 Administered to Healthy Male Volunteers and Postmenopausal Female Volunteers

Next Previous
X
Search
Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KER-047 Administered to Healthy Male Volunteers and Postmenopausal Female Volunteers

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KER 047 (Primary)
  • Indications Anaemia; Fibrodysplasia ossificans progressiva
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Keros Therapeutics

    • Most Recent Events

    • 08 Dec 2020 Results assessing evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single and multiple ascending dose levels of KER-047 in healthy participants, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 07 Dec 2020 Results published in a Keros Therapeutics media release.
    • 07 Dec 2020 According to a Keros Therapeutics media release, company has presented data from this trial at the virtual 62nd American Society of Hematology Annual Meeting and Exposition ("ASH").

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top